Classified within cash equivalents and current marketable securities.
(5)
Includes $
1,181
million and $
1,217
million classified as non-current other liabilities as of March 30, 2025 and December 29, 2024, respectively. Includes $
50
million classified as current liabilities as of March 30, 2025.
(6)
Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense.
The Company's cash, cash equivalents and current marketable securities as of March 30, 2025 comprised:
(1)
Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings.
(2)
Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.
As of the fiscal year ended December 29, 2024, the carrying amount of cash, cash equivalents and current marketable securities was approximately the same as the estimated fair value.
Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs.
The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as current marketable securities.
The contractual maturities of the available for sale securities as of March 30, 2025 are as follows:
Tabl
e of Contents
Financial instruments not measured at fair value
The following financial liabilities are held at carrying amount on the consolidated balance sheet as of March 30, 2025:
Tabl
e of Contents
(1)
In the fiscal first quarter of 2025, the Company issued senior unsecured notes for approximately $
9.2
billion. The net proceeds from this offering were used to fund the Intra-Cellular Therapies, Inc. acquisition which closed on April 2, 2025, and for general corporate purposes.
The weighted average effective interest rate on non-current debt is
3.58
%.
The excess of the carrying value over the estimated fair value of debt was $
2.0
billion at December 29, 2024.
Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.
The current debt balance as of March 30, 2025, includes $
10.9
billion of commercial paper which has a weighted average interest rate of
4.28
% and a weighted average maturity of approximately
two months
.
Note 5 —
Income taxes
The worldwide effective income tax rates for the fiscal first quarter of 2025 and 2024 were
19.3
% and
12.4
%, respectively. The increase in the consolidated tax rate is primarily due to more income in higher tax jurisdictions,